Evidence map›Paper›PMID 39329689›Full record

ArticleBioengineering (Basel, Switzerland)2024

Mesenchymal Stem Cell-Conditioned Media-Loaded Microparticles Enhance Acute Patency in Silk-Based Vascular Grafts.

Katherine L Lorentz, Ande X Marini, Liza A Bruk, Prerak Gupta, Biman B Mandal, Morgan V DiLeo, Justin S Weinbaum, Steven R Little, David A Vorp

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Katherine L LorentzDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Ande X MariniDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0001-7198-9344
Liza A BrukDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Prerak GuptaDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15261, USA.
Biman B MandalDepartment of Biosciences and Bioengineering, Indian Institute of Technology Guwahati, Guwahati 781039, Assam, India.
Morgan V DiLeoDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0002-8949-8305
Justin S WeinbaumDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0002-0626-6083
Steven R LittleDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15261, USA.
David A VorpDepartment of Bioengineering, University of Pittsburgh, Pittsburgh, PA 15261, USA.ORCID 0000-0002-6467-2151

Funding

Cardiovascular Bioengineering Training ProgramT32HL076124 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI SANJEEV G SHROFF · 2005 to 2026
$7.0M
Artificial Stem Cells for Vascular Tissue EngineeringR01HL130077 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VORP, DAVID ALAN · 2016 to 2019
$1.5M
Preclinical optimization and design for manufacturability of immunoregulatory tissue-engineered vascular graftsR61HL154102 · NHLBI · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI VORP, DAVID ALAN · 2020 to 2021
$757k
NHLBI NIH HHS R01 HL130077NHLBI NIH HHS R61 HL154102NHLBI NIH HHS T32 HL076124
6 · The paper itself

Abstract

Coronary artery disease leads to over 360,000 deaths annually in the United States, and off-the-shelf bypass graft options are currently limited and/or have high failure rates. Tissue-engineered vascular grafts (TEVGs) present an attractive option, though the promising mesenchymal stem cell (MSC)-based implants face uncertain regulatory pathways. In this study, "artificial MSCs" (ArtMSCs) were fabricated by encapsulating MSC-conditioned media (CM) in poly(lactic-co-glycolic acid) microparticles. ArtMSCs and control microparticles (Blank-MPs) were incubated over 7 days to assess the release of total protein and the vascular endothelial growth factor (VEGF-A); releasates were also assessed for cytotoxicity and promotion of smooth muscle cell (SMC) proliferation. Each MP type was loaded in previously published "lyogel" silk scaffolds and implanted as interposition grafts in Lewis rats for 1 or 8 weeks. Explanted grafts were assessed for patency and cell content. ArtMSCs had a burst release of protein and VEGF-A. CM increased proliferation in SMCs, but not after encapsulation. TEVG explants after 1 week had significantly higher patency rates with ArtMSCs compared to Blank-MPs, but similar to unseeded lyogel grafts. ArtMSC explants had lower numbers of infiltrating macrophages compared to Blank-MP explants, suggesting a modulation of inflammatory response by the ArtMSCs. TEVG explants after 8 weeks showed no significant difference in patency among the three groups. The ArtMSC explants showed higher numbers of SMCs and endothelial cells within the neotissue layer of the graft compared to Blank-MP explants. In sum, while the ArtMSCs had positive effects acutely, efficacy was lost in the longer term; therefore, further optimization is needed.

Indexed as

cardiovascular diseasecoronary artery diseasemesenchymal stem cellsregenerative medicinetissue-engineered vascular graft

Identifiers

PMID39329689
PMCPMC11428691

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.